Value Propositions

Cancer Treatment Centers of America (CTCA) in Philadelphia, PA, is the first US center to investigate the use of nanotherapy for the treatment of metastatic lung cancer.
Read Article


Empire Genomics is developing the first molecular diagnostic test for multiple myeloma (MM) using a novel genomic biomarker from Emory University that will allow providers to select the right treatments for the right patients based on their genetic profile.
Read Article

The search for better diagnostic tools for prostate cancer continues, with current test modalities leaving much room for improvement.
Read Article

Early treatment response is a strong predictor of long-term outcomes in children with acute myeloid leukemia (AML); it can further help to determine whether an aggressive treatment approach is needed.
Read Article

In September, Cardinal Health Specialty Solutions announced the launch of a new collaboration initiative with Health Alliance Plan (HAP) and Physician Resource Management to establish an evidence-based clinical pathways program aimed at reducing the costs of cancer care while improving quality of care.
Read Article

The Institute of Medicine (IOM) recently held a roundtable discussion on the status of genome-based drug development.
Read Article

The recent discovery of 3 subtypes of high-grade serous ovarian cancer (HGSOC) by researchers at Dana-Farber Cancer Institute will soon enable oncologists to determine which of their patients with HGSOC—the most common type of ovarian cancer—are most likely to benefit from a certain class of drugs.
Read Article



Page 6 of 11